Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 67

Sort by

Sort Order Select

Journal Articles

Mosunetuzumab with Response-Driven Lenalidomide Augmentation As First-Line Therapy for Symptomatic Follicular or Marginal Zone Lymphoma: Interim Analysis of a Multi-Center Phase 2 Study

Adam J. Olszewski, Matthew Matasar, Scott F Huntington, Thomas Ollila, Ari Pelcovits, Yun Kyoung Tiger, John L. Reagan, Anna Dorota Chorzalska, John Morgan, Makayla R Pardo, Jessica McMahon, Stephen Donnelly, Caylee Carmody, Jeannine Margolis, Charles Milrod, Patrycja M. Dubielecka

Blood (2024) 144 (Supplement 1): 1644.

https://doi.org/10.1182/blood-2024-193022

Published: 2024

Journal Articles

Circulating Biomarkers and CD8+ T-Cell Subpopulations Reveal Evolving Phases of Immune Response in Patients Receiving Mosunetuzumab for Previously Untreated B-Cell Lymphoma

Charles Milrod, Anna Dorota Chorzalska, John Morgan, Makayla R Pardo, Christina Raker, Thomas Ollila, Seo-Ho Lee, Ari Pelcovits, John L. Reagan, Jessica McMahon, Stephen Donnelly, Caylee Carmody, Jeannine Margolis, Matthew Matasar, Scott F Huntington, Patrycja M. Dubielecka, Adam J. Olszewski

Blood (2024) 144 (Supplement 1): 1614.

https://doi.org/10.1182/blood-2024-193023

Published: 2024

Journal Articles

Deciphering the AML Niche: RNA Sequencing and Spatial Transcriptomics Reveal Diverse Transcriptomic Landscapes in Responders Vs. Non-Responders

Makayla R Pardo, Dennis M Bonal, Seo-Ho Lee, Anna Dorota Chorzalska, Valeria Brown, John L. Reagan, Diana Olguta Treaba, Patrycja M. Dubielecka

Blood (2024) 144 (Supplement 1): 64.

https://doi.org/10.1182/blood-2024-208213

Published: 2024

Journal Articles

Early Experience with Mosunetuzumab and Managing Cytokine Release Syndrome: Results of a Single Center Retrospective

Victoria A Gill, Christina Raker, Adam J. Olszewski, John L. Reagan, Ari Pelcovits

Blood (2024) 144 (Supplement 1): 2273.

https://doi.org/10.1182/blood-2024-201724

Published: 2024

Journal Articles

A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A Myelomatch Treatment Trial: ECOG-ACRIN MM20A-EA02

Jessica Kaplan Altman, Zhuoxin Sun, Alexander E. Perl, Richard Little, Steven D. Gore, Laura C. Michaelis, Geoffrey L. Uy, Yasmin Abaza, Sameem Abedin, John L. Reagan, Ehab L. Atallah, Selina Luger, Mark R. Litzow

Blood (2024) 144 (Supplement 1): 2907.1.

https://doi.org/10.1182/blood-2024-199701

Published: 2024

Journal Articles

Engrafted JAK2V617F Clone Hijacks Resident Non-Mutated Hematopoietic System to Drive Myeloproliferative Neoplasm

Dennis M Bonal, Anna Dorota Chorzalska, Alissa Oakes, Makayla R Pardo, Seo-Ho Lee, Michael Y Clarke, Max Petersen, Hyunju Oh, Valeria Brown, Diana Olguta Treaba, John L. Reagan, Adam J. Olszewski, Mark Dooner, John Morgan, Joslyn Mills, Paul Bertone, Patrycja M Dubielecka

Blood (2024) 144 (Supplement 1): 754.

https://doi.org/10.1182/blood-2024-208312

Published: 2024

Journal Articles

LRP1 / SDC1 / TGM2/LGALS3 Stromal Signature Is Linked to Favorable Induction Chemotherapy Response in AML

Seo-Ho Lee, Dennis M Bonal, Diana Olguta Treaba, Makayla R Pardo, Anna Dorota Chorzalska, John L. Reagan, Adam J. Olszewski, Patrycja M. Dubielecka

Blood (2024) 144 (Supplement 1): 5657.

https://doi.org/10.1182/blood-2024-207910

Published: 2024

Journal Articles

Dysfunctional Stromal Pathways Mark Early Changes within the Bone Marrow Microenvironment in JAK2 V617F-Driven Model of Myeloproliferative Neoplasm

Dennis M Bonal, Anna Dorota Chorzalska, Alissa Oakes, Makayla Pardo, Zoe Creane, Seo-Ho Lee, Omonike Oyelola, John L. Reagan, Adam Olszewski, Rabin Niroula, Stephen Donnelly, Joslyn Mills, Paul Bertone, Patrycja M Dubielecka

Blood (2023) 142 (Supplement 1): 3150.

https://doi.org/10.1182/blood-2023-189298

Published: 2023

Journal Articles

Inpatient Versus Outpatient Administration of Hypomethylating Agents and Venetoclax in Acute Myeloid Leukemia

Pranavi Sanka, Pamela Egan, Rabin Niroula, Inna Yakirevich, David Gardner, John L. Reagan

Blood (2023) 142 (Supplement 1): 4229.

https://doi.org/10.1182/blood-2023-184948

Published: 2023

Journal Articles

Alterations in Immune Cell Composition during First-Line Therapy with Mosunetuzumab for Follicular or Marginal Zone Lymphoma

Adam J Olszewski, Thomas Ollila, Ari Pelcovits, Anna Dorota Chorzalska, John Morgan, Jessica McMahon, Stephen Donnelly, Scott F. Huntington, Matthew Matasar, John L. Reagan, Charles Milrod, Patrycja M. Dubielecka

Blood (2023) 142 (Supplement 1): 1651.

https://doi.org/10.1182/blood-2023-181418

Published: 2023

Journal Articles

Removing Transfusion Dependence As a Barrier to Hospice Enrollment (BRUOG-407)

Pamela Egan, Ari Pelcovits, Caitlyn Krar, Stephen Donnelly, Lila Rubin, Rabin Niroula, John L. Reagan, Dana Guyer, Adam J Olszewski, Thomas W LeBlanc

Blood (2023) 142 (Supplement 1): 259.

https://doi.org/10.1182/blood-2023-187645

Published: 2023

Journal Articles

Sry-Box Transcription Factor 9 (SOX9)-Driven Mesenchymal Stromal Cell Differentiation Signature As a Determinant of Induction Chemotherapy Responsiveness in Acute Myeloid Leukemia Core Bone Marrow Biopsies

Seo-Ho Lee, Dennis M Bonal, Diana Olguta Treaba, Anna Dorota Chorzalska, Makayla Pardo, John L. Reagan, Adam J Olszewski, Patrycja M. Dubielecka

Blood (2023) 142 (Supplement 1): 4299.

https://doi.org/10.1182/blood-2023-189679

Published: 2023

Journal Articles

Loss of Complement Factor I (Cfi) a Negative Regulator of Complement Cascade Activity Exacerbates JAK2V617F-Dependent Phenotype

Alissa Oakes, Dennis M Bonal, Zoe Creane, Hyunju Oh, Anna Dorota Chorzalska, Brooke Sadler, John L. Reagan, Rabin Niroula, Adam J Olszewski, Gabriel Haller, Stephen Donnelly, Patrycja M Dubielecka

Blood (2023) 142 (Supplement 1): 3149.

https://doi.org/10.1182/blood-2023-189483

Published: 2023

Journal Articles

Fractionated Gemtuzumab Ozogamicin Followed By Non-Engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia

John L. Reagan, Rabin Niroula, Jessica McMahon, Pamela Egan, Inna Yakirevich, Mandy Pereira, Ari Pelcovits, Jeannine Margolis, Ashlee Sturtevant, Peter J. Quesenberry, Loren D. Fast

Blood (2023) 142 (Supplement 1): 6874.

https://doi.org/10.1182/blood-2023-177759

Published: 2023

Journal Articles

Removing Transfusion Dependence As a Barrier to Hospice Enrollment (BRUOG-407)

Pamela C Egan, Aryeh Pelcovits, Thomas W. Leblanc, Caitlyn Krar, Stephen Donnelly, Lila Rubin, Adam Olszewski, John L Reagan, Rabin Niroula

Blood (2022) 140 (Supplement 1): 7946–7947.

https://doi.org/10.1182/blood-2022-156951

Published: 2022

Journal Articles

Low Dose Irradiation Exhibits a Curative Potential in ABI1-Loss Driven Model of Myeloproliferative Neoplasm

Anna D Chorzalska, John Morgan, Diana O Treaba, Damali Simon-Ponte, Omonike Oyelola, John L Reagan, Patrycja M Dubielecka

Blood (2022) 140 (Supplement 1): 5880–5882.

https://doi.org/10.1182/blood-2022-170964

Published: 2022

Journal Articles

Assessment of Emergency Department Care for Patients with Acute Pain Crisis after the Formation of a Multidisciplinary Team

Taneisha Wilson, Katie Cherenzia, John L. Reagan, Dana L. Guyer, Catherine Trimbur, Jessica Nagy, Jon Meideros, Andrew Buksar, Priscilla Eskridge, David Gardner, Ilse Jenouri, Patrick T. McGann

Blood (2022) 140 (Supplement 1): 5013–5014.

https://doi.org/10.1182/blood-2022-170951

Published: 2022

Journal Articles

Complement Factor I (CFI) Deficiency Is Linked to Alterations in Humoral Immunity and Accelerated Development of JAK2V617F-Dependent Phenotype

Alissa Oakes, Anna D Chorzalska, Dennis M Bonal, John L Reagan, Patrycja M Dubielecka

Blood (2022) 140 (Supplement 1): 8721–8722.

https://doi.org/10.1182/blood-2022-170675

Published: 2022

Journal Articles

Non-Relapse Mortality and Quality of Life with Shared Care after Allogeneic Hematopoietic Cell Transplantation: A Randomized Control Trial

Blood (2022) 140 (Supplement 1): 2135–2136.

https://doi.org/10.1182/blood-2022-166996

Published: 2022

Journal Articles

Successful Engraftment of Murine JAK2V617F MPN-like Disease into Unconditioned Mice

Dennis M Bonal, Anna D Chorzalska, Alissa Oakes, Valeria Brown, John L Reagan, Seo-Ho Lee, Patrycja M Dubielecka

Blood (2022) 140 (Supplement 1): 12158–12159.

https://doi.org/10.1182/blood-2022-170611

Published: 2022

NARROW

Mosunetuzumab with Response-Driven Lenalidomide Augmentation As First-Line Therapy for Symptomatic Follicular or Marginal Zone Lymphoma: Interim Analysis of a Multi-Center Phase 2 Study

Circulating Biomarkers and CD8+ T-Cell Subpopulations Reveal Evolving Phases of Immune Response in Patients Receiving Mosunetuzumab for Previously Untreated B-Cell Lymphoma

Deciphering the AML Niche: RNA Sequencing and Spatial Transcriptomics Reveal Diverse Transcriptomic Landscapes in Responders Vs. Non-Responders

Early Experience with Mosunetuzumab and Managing Cytokine Release Syndrome: Results of a Single Center Retrospective

A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A Myelomatch Treatment Trial: ECOG-ACRIN MM20A-EA02

Engrafted JAK2V617F Clone Hijacks Resident Non-Mutated Hematopoietic System to Drive Myeloproliferative Neoplasm

LRP1 / SDC1 / TGM2/LGALS3 Stromal Signature Is Linked to Favorable Induction Chemotherapy Response in AML

Dysfunctional Stromal Pathways Mark Early Changes within the Bone Marrow Microenvironment in JAK2 V617F-Driven Model of Myeloproliferative Neoplasm

Inpatient Versus Outpatient Administration of Hypomethylating Agents and Venetoclax in Acute Myeloid Leukemia

Alterations in Immune Cell Composition during First-Line Therapy with Mosunetuzumab for Follicular or Marginal Zone Lymphoma

Removing Transfusion Dependence As a Barrier to Hospice Enrollment (BRUOG-407)

Sry-Box Transcription Factor 9 (SOX9)-Driven Mesenchymal Stromal Cell Differentiation Signature As a Determinant of Induction Chemotherapy Responsiveness in Acute Myeloid Leukemia Core Bone Marrow Biopsies

Loss of Complement Factor I (Cfi) a Negative Regulator of Complement Cascade Activity Exacerbates JAK2V617F-Dependent Phenotype

Fractionated Gemtuzumab Ozogamicin Followed By Non-Engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia

Removing Transfusion Dependence As a Barrier to Hospice Enrollment (BRUOG-407)

Low Dose Irradiation Exhibits a Curative Potential in ABI1-Loss Driven Model of Myeloproliferative Neoplasm

Assessment of Emergency Department Care for Patients with Acute Pain Crisis after the Formation of a Multidisciplinary Team

Complement Factor I (CFI) Deficiency Is Linked to Alterations in Humoral Immunity and Accelerated Development of JAK2V617F-Dependent Phenotype

Non-Relapse Mortality and Quality of Life with Shared Care after Allogeneic Hematopoietic Cell Transplantation: A Randomized Control Trial

Successful Engraftment of Murine JAK2V617F MPN-like Disease into Unconditioned Mice

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only